Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
Miruna Sasu spent more than 20 years as a digital health and innovation expert at life sciences companies—then came a realization
Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible.
A collaboration of 10 healthcare research organizations has demonstrated that real-world endpoints can be used to describe patient outcomes that are analogous to results generated through conventional endpoints in clinical trials.
The vast majority of patients with prostate cancer in the United States don't receive androgen deprivation therapy injections on time. Up to 84% of injections are delayed for patients on a 28-day schedule, according to an authoritative study published in the The Journal of Urology.
Community oncology practices in the United States are reeling from a sharp decrease in business—whether you look at new patients, chemotherapy visits, or non-chemo visits—the result of reduced activity and stay-at-home orders across the country to mitigate the spread of SARS-CoV-2.
Ten health care research organizations, with help from FDA and NCI, have developed a set of common definitions for real-world endpoints, including overall survival, progression-free survival, and other non-traditional endpoints.
The growth of personalized medicine in oncology continues to fuel a shift from traditional chemotherapies to immunotherapy. Currently, there are more than 30 immunotherapies approved for use in the United States, with more than 2,300 immunotherapy clinical trials listed on ClinicalTrials.gov.
In an unprecedented use of real-world data, researchers at the University of Pennsylvania and Flatiron Health have determined that oncologists are responding quickly to label restrictions announced by FDA.
The number of approved cancer therapies continues to rise, with 63 cancer drugs launched within the past five years.
